Pancreatic cancer: From pathogenesis to cure

Best Practice and Research: Clinical Gastroenterology

Volumn 21, Issue 6, 2007, Pages 997-1014

  Ducreux, Michel ^b   Boige, Valérie ^b   Goéré, Diane ^b   Deutsch, Eric ^b   Ezra, Patrick ^b   Elias, Dominique ^b   Malka, David ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b NONE

Author keywords

drug therapy; immunotherapy; pancreatic neoplasms; radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CELECOXIB; CETUXIMAB; CISPLATIN; CURCUMIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; MITOMYCIN C; ONYX 015; PACLITAXEL; PLACEBO; TOLFENAMIC ACID; UFT;

ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; BACTERIAL INFECTION; BLOOD TOXICITY; CANCER LOCALIZATION; CANCER MORTALITY; CAUSE OF DEATH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CYTOTOXICITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUODENUM PERFORATION; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS CARCINOMA; PATHOGENESIS; RECTUM CANCER; SINGLE DRUG DOSE; SURVIVAL RATE; UNITED STATES; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; CANCER INVASION; CANCER STAGING; DISEASE FREE SURVIVAL; PANCREAS RESECTION; PANCREAS TUMOR; PATHOLOGY; PATIENT SELECTION; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; HUMANS; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PANCREATECTOMY; PANCREATIC NEOPLASMS; PATIENT SELECTION; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 36749101954     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2007.10.025     Document Type: Article

References (116)

1. Evans D.B., Abbruzzese J.L., and Willett C.G. Cancer of the pancreas. In: deVita Jr. V.T., Hellman S., and Rosenberg S.A. (Eds). Principles and Practice of Oncology (2001), Lippincott Williams and Wilkins, Philadelphia 1126-1161
2. Bramhall S.R., Allum W.H., Jones A.G., et al. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 82 (1995) 111-115
3. Bramhall S.R., Dunn J., and Neoptolemos J.P. Epidemiology of pancreatic cancer. In: Beger H.G., Warshaw A., and Carr-Locke D.L. (Eds). The Pancreas (1998), Blackwell Scientific, Boston 889-906
4. Fernandez E., La Vecchia C., Porta M., et al. Trends in pancreatic cancer mortality in Europe, 1955-1989. Int J Cancer 57 (1994) 786-792
5. Jemal A., Thomas A., Murray T., et al. Cancer statistics, 2002. CA Cancer J Clin 52 (2002) 23-47
6. Parkin D.M., Bray F.I., and Devesa S.S. Cancer burden in the year 2000. The global picture. Eur J Cancer 37 Suppl. 8 (2001) S4-S66
7. Ferlay J, Bray F, Pisani P, et al. GLOBOSCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. 2001.
8. Lowenfels A.B., Maisonneuve P., Cavallini G., et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 328 (1993) 1433-1437
9. Lowenfels A.B., Maisonneuve P., Dimagno E.P., et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 89 (1997) 442-446
10. Malka D., Hammel P., Maire F., et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 51 (2002) 849-852
11. Wong T., Howes N., Threadgold J., et al. Molecular diagnosis of early pancreatic ductal adenocarcinoma in high-risk patients. Pancreatology 1 (2001) 486-509
12. Coughlin S.S., Calle E.E., Patel A.V., et al. Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control 11 (2000) 915-923
13. Harnack L.J., Anderson K.E., Zheng W., et al. Smoking, alcohol, coffee, and tea intake and incidence of cancer of the exocrine pancreas: the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev 6 (1997) 1081-1086
14. Lowenfels A.B., Maisonneuve P., Whitcomb D.C., et al. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA 286 (2001) 169-170
15. Bramhall S.R., and Neoptolemos J.P. Advances in diagnosis and treatment of pancreatic cancer. Gastroenterologist 3 (1995) 301-310
16. Wong A., Chan A., and Arthur K. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas. Cancer Treat Rep 71 (1987) 749-750
17. Haycox A., Lombard M., Neoptolemos J., et al. Review article: current practice and future perspectives in detection and diagnosis of pancreatic cancer. Aliment Pharmacol Ther 12 (1998) 937-948
18. Magee C.J., Greenhalf W., Howes N., et al. Molecular pathogenesis of pancreatic ductal adenocarcinoma and clinical implications. Surg Oncol 10 (2001) 1-23
19. Edis A.J., Kiernan P.D., and Taylor W.F. Attempted curative resection of ductal carcinoma of the pancreas. Review of Mayo Clinic experience, 1951-1975. Mayo Clin Proc 55 (1980) 531-536
20. Janes R.H., Niederhuber J.E., Chmiel J.S., et al. National patterns of care for pancreatic cancer. Results of a survey by the commission on cancer. Ann Surg 223 (1996) 261-272
21. Manabe T., Ohshio G., Baba N., et al. Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas. Cancer 64 (1989) 1132-1137
22. Baumel H., Huguier M., Manderscheid J.C., et al. Results of resection for cancer of the exocrine pancreas: a study from the French Association of Surgery. Br J Surg 81 (1994) 102-107
23. Haller D.G. Chemotherapy for advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 56 (2003) 16-23
24. Griffin J.F., Smalley S.R., Jewell W., et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 66 (1990) 56-61
25. Westerdahl J., Andren-Sandberg A., and Ihse I. Recurrence of exocrine pancreatic cancer - local or hepatic?. Hepatogastroenterology 40 (1993) 384-387
26. Bakkevold K.E., Pettersen A., Arnesjo B., et al. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of Vater. Br J Surg 77 (1990) 725-730
27. Bakkevold K.E., Arnesjo B., Dahl O., et al. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater - results of a controlled, prospective, randomised multicentre study. Eur J Cancer 29A (1993) 698-703
28. Neoptolemos J.P., Dunn J.A., Stocken D.D., et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358 (2001) 1576-1585
29. Neoptolemos J.P., Dunn J.A., Moffitt D.D., et al. ESPAC-1 interim results: a European, randomised study to assess the roles of adjuvant chemotherapy (5FU + folinic acid) and adjuvant chemoradiation (40 Gy + 5FU) in resectable pancreatic cancer. Proc Am Soc Clin Oncol 19 (2000) 238a
30. Neoptolemos J.P., Stocken D.D., Dunn J.A., et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 234 (2001) 758-768
31. Neoptolemos J.P., Stocken D.D., Friess H., et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350 (2004) 1200-1210
32. Oettle H., Post S., Neuhaus P., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297 (2007) 267-277
33. Kosuge T., Ueno H., Matsuyama Y., et al. A randomized phase III study comparing gemcitabine monotherapy with observation in patients with resected pancreatic cancer. Eur J Cancer 5 (2007) 260
34. Regine W.F., and Abrams R.A. Adjuvant therapy for pancreatic cancer: current status, future directions. Semin Oncol 33 (2006) S10-S13
35. Yoshitomi H., Togawa A., Kimura F., et al. A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur (UFT) and gemcitabine (GEM) vs. gemcitabine alone in patients with resected pancreatic cancer. Proc Am Soc Clin Oncol 25 (2007) 4542
36. Gansauge F., Link K.H., Rilinger N., et al. Adjuvant regional chemotherapy in resected advanced pancreas carcinoma. Chirurgia 67 (1996) 362-365
37. Ishikawa O., Ohigashi H., Sasaki Y., et al. Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas. Am J Surg 168 (1994) 361-364
38. Ishikawa O., Ohigashi H., Imaoka S., et al. Regional chemotherapy to prevent hepatic metastasis after resection of pancreatic cancer. Hepatogastroenterology 44 (1997) 1541-1546
39. Link K.H., Formentini A., Gansauge F., et al. Regional celiac artery infusion as adjuvant treatment after pancreatic cancer resection. Digestion 58 (1997) 529-532
40. Alfieri S., Morganti A.G., Di Giorgio A., et al. Improved survival and local control after intraoperative radiation therapy and postoperative radiotherapy: a multivariate analysis of 46 patients undergoing surgery for pancreatic head cancer. Arch Surg 136 (2001) 343-347
41. Johnstone P.A., and Sindelar W.F. Patterns of disease recurrence following definitive therapy of adenocarcinoma of the pancreas using surgery and adjuvant radiotherapy: correlations of a clinical trial. Int J Radiat Oncol Biol Phys 27 (1993) 831-834
42. Lee J.H., Whittington R., Williams N.N., et al. Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. Int J Radiat Oncol Biol Phys 47 (2000) 945-953
43. Mehta V.K., Fisher G.A., Ford J.M., et al. Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. Int J Radiat Oncol Biol Phys 48 (2000) 1483-1487
44. Willett C.G., Lewandrowski K., Warshaw A.L., et al. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg 217 (1993) 144-148
45. Klinkenbijl H.L., Jeekel J., Sahmoud T., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 230 (1999) 776-782
46. Moertel C.G., Childs D.S., Reitemeier R.J., et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2 (1969) 865-867
47. Moertel C.G., Frytak S., Hahn R.G., et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 Rads) radiation alone, moderate dose radiation (4000 Rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. The Gastrointestinal Tumor Study Group. Cancer 48 (1981) 1705-1710
48. Gastrointestinal tumor study group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 59 (1987) 2006-2010
49. Kalser M.H., and Ellenberg S.S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120 (1985) 899-903 [Erratum in Arch Surg 1986; 121: 1045]
50. Abrams R.A., Grochow L.B., Chakravarthy A., et al. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. Int J Radiat Oncol Biol Phys 44 (1999) 1039-1046
51. Paulino A.C. Resected pancreatic cancer treated with adjuvant radiotherapy with or without 5-fluorouracil: treatment results and patterns of failure. Am J Clin Oncol 22 (1999) 489-494
52. Sohn T.A., Yeo C.J., Cameron J.L., et al. Resected adenocarcinoma of the pancreas - 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4 (2000) 567-579
53. Van Laethem J.L., Demols A., Gay F., et al. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study. Int J Radiat Oncol Biol Phys 56 (2003) 974-980
54. Breslin T.M., Hess K.R., Harbison D.B., et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 8 (2001) 123-132
55. Hoffman J.P., Weese J.L., Solin L.J., et al. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg 169 (1995) 71-77
56. Hoffman J.P., Lipsitz S., Pisansky T., et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 16 (1998) 317-323
57. Mornex F., Girard N., Scoazec J.Y., et al. Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: the French SFRO-FFCD 97-04 phase II trial. Int J Radiat Oncol Biol Phys 65 (2006) 1471-1478
58. Talamonti M.S., Small Jr. W., Mulcahy M.F., et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 13 (2006) 150-158
59. Pestalozzi B.C., Heinrich S., Schäfer M., et al. Neoadjuvant chemotherapy for resectable adenocarcinoma of the pancreatic head - a prospective phase II trial. Proc Am Soc Clin Oncol 25 (2007) 4610
60. Talamonti M.S., Catalano P.J., Vaughn D.J., et al. Eastern Cooperative Oncology Group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol 18 (2000) 3384-3389
61. Sohn T.A., Lillemoe K.D., Cameron J.L., et al. Reexploration for periampullary carcinoma: resectability, perioperative results, pathology, and long-term outcome. Ann Surg 229 (1999) 393-400
62. Cohen L., Hendrickson F.R., Lennox A.J., et al. Pancreatic cancer: treatment with neutron irradiation alone and with chemotherapy. Radiology 200 (1996) 627-630
63. Cohen S.J., Dobelbower R., Lipsitz S., et al. A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group Study E8282. Int J Radiat Oncol Biol Phys 62 (2005) 1345-1350
64. Mehta V.K., Poen J.C., Ford J.M., et al. Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. Am J Clin Oncol 24 (2001) 155-159
65. Boz G., De Paoli A., Innocente R., et al. Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma. Int J Radiat Oncol Biol Phys 51 (2001) 736-740
66. Luderhoff E.C., Gonzalez G.D., and Bakker P. Pilot study in locally advanced unresectable pancreas carcinoma using a combination of accelerated radiotherapy and continuous infusion of 5-fluorouracil. Radiother Oncol 40 (1996) 241-243
67. Prott F.J., Schonekaes K., Preusser P., et al. Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study. Br J Cancer 75 (1997) 597-601
68. Penberthy D.R., Rich T.A., Shelton III C.H., et al. A pilot study of chronomodulated infusional 5-fluorouracil chemoradiation for pancreatic cancer. Ann Oncol 12 (2001) 681-684
69. Shinchi H., Takao S., Noma H., et al. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 53 (2002) 146-150
70. Chauffert B., Mornex F., Bonnetain F., et al. Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: a FFCD-SFRO study. Proc Am Soc Clin Oncol 24 (2006) 4008
71. Dunst J., Reese T., Sutter T., et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 20 (2002) 3983-3991
72. Saif M.W., Eloubeidi M.A., Russo S., et al. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol 23 (2005) 8679-8687
73. Saito Y., Milross C.G., Hittelman W.N., et al. Effect of radiation and paclitaxel on p53 expression in murine tumors sensitive or resistant to apoptosis induction. Int J Radiat Oncol Biol Phys 38 (1997) 623-631
74. Rich T.A., Harris J., Abrams R., et al. A phase II study of external irradiation and weekly paclitaxel for non-metastatic, unresectable pancreatic cancer: a preliminary report of RTOG protocol 98-12. Int J Radiat Oncol Biol Phys 51 (2001) 29
75. Willett C.G., Safran H., Abrams R.A., et al. Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials. Int J Radiat Oncol Biol Phys 56 (2003) 31-37
76. Gnant M, Kuehrer I, Teleky B, et al. Neoadjuvant chemotherapy of locally advanced pancreatic cancer leads to 67% 3-year survival. In Proceedings of the GI ASCO Symposium, 2004, Abstract no. 96.
77. Ashamalla H, Mokhtar B, Dosik D, et al. Hyperfractionated concomitant in-field boost with gemcytabine, paclitaxel followed by surgery in locally advanced pancreatic cancer. In Proceedings of the GI ASCO Symposium, 2004, Abstract no. 158.
78. Epelbaum R., Rosenblatt E., Nasrallah S., et al. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol 81 (2002) 138-143
79. Ikeda M., Okada S., Tokuuye K., et al. A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer 86 (2002) 1551-1554
80. McGinn C.J., Zalupski M.M., Shureiqi I., et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19 (2001) 4202-4208
81. Huang P., Chubb S., Hertel L.W., et al. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51 (1991) 6110-6117
82. Huang N.J., and Hittelman W.N. Transient inhibition of chromosome damage repair after ionizing radiation by gemcitabine. Proc Am Assoc Cancer Res 36 (2001) 612
83. Crane C.H., Wolff R.A., Abbruzzese J.L., et al. Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. Semin Oncol 28 (2001) 25-33
84. Touroutoglou N., Gravel D., Raber M.N., et al. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol 9 (1998) 1003-1008
85. Mason K.A., Hunter N.R., Milas M., et al. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 3 (1997) 2431-2438
86. Mason K.A., Milas L., Hunter N.R., et al. Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys 44 (1999) 1125-1135
87. Li C.P., Chao Y., Chi K.H., et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 57 (2003) 98-104
88. Haddock MG, Swaminathan R, Alberts SR, et al. Phase II study of gemcitabine (Gem), cisplatin (Cis) and radiation therapy (RT) in patients with locally advanced pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) study. In Proceedings of the GI ASCO Symposium, 2004, Abstract no. 169.
89. Michael M., Price T., Leong T., et al. Phase I trial of capecitabine and gemcitabine with concurrent radical radiotherapy in locally advanced pancreatic cancer: final results. Eur J Cancer 5 (2007) 3543
90. Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Gastrointestinal Tumor Study Group. Cancer 56 (1985) 2563-2568
91. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 80 (1988) 751-755
92. Ishii H., Okada S., Tokuuye K., et al. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 79 (1997) 1516-1520
93. Kamthan A.G., Morris J.C., Dalton J., et al. Combined modality therapy for stage II and stage III pancreatic carcinoma. J Clin Oncol 15 (1997) 2920-2927
94. Klaassen D.J., MacIntyre J.M., Catton G.E., et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil. An Eastern Cooperative Oncology Group Study. J Clin Oncol 3 (1985) 373-378
95. Kindler HL, Niedzwiecki D, Hollis D, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. In Proceedings of the GI ASCO symposium, 2007, Abstract no. 108.
96. Philip P.A., Benedetti C., Fenoglio-Preiser C., et al. Phase III study of gemcitabine (G) plus cetuximab (C) versus gemcitabine in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (PC): SWOG S025 study. Proc Am Soc Clin Oncol 25 (2007) [LBA4509]
97. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (2007) 1960-1966
98. Gorski D.H., Beckett M.A., Jaskowiak N.T., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59 (1999) 3374-3378
99. Wey J.S., Fan F., Gray M.J., et al. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer 104 (2005) 427-438
100. Willett C.G., Kozin S.V., Duda D.G., et al. Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. Semin Oncol 33 (2006) S35-S40
101. Crane C.H., Ellis L.M., Abbruzzese J.L., et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 24 (2006) 1145-1151
102. Krempien R., Munter M.W., Timke C., et al. Cetuximab in combination with intensity modulated radiotherapy (IMRT) and gemcitabine for patients with locally advanced pancreatic cancer: a prospective phase II trial [PARC-Study ISRCTN56652283]. Proc Am Soc Clin Oncol 25 (2007) 4573
103. Plunkett W., Huang P., and Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs 6 Suppl. 6 (1995) 7-13
104. Gastrointestinal tumour study group. Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group. J Clin Oncol 4 (1986) 1794-1798
105. Burris H.A.I., Moore J.A., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 (1997) 2403-2413
106. Carmichael J., Fink U., Russell R.C., et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73 (1996) 101-105
107. Casper E.S., Green M.R., Kelsen D.P., et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12 (1994) 29-34
108. Oster M.W., Gray R., Panasci L., et al. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM). Cancer 57 (1986) 29-33
109. Abbruzzese J., Kurzrock R., McConkey D., et al. Are there rational novel targets for pancreatic cancer therapeutics? Observations from the M.D. Anderson Cancer Center SPORE in pancreatic cancer. Eur J Cancer 5 (2007) 149
110. Li L., Aqqarwal B.B., Shishodia S., et al. Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 101 (2004) 2351-2362
111. Laheru D.A., Pardoll D.M., and Jaffee E.M. Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology. Mol Cancer Ther 4 (2005) 1645-1652
112. Krinsky M.L., and Binmoeller K.F. EUS-guided investigational therapy for pancreatic cancer. Gastrointest Endosc 52 (2000) S35-S38
113. Chang K.J., Nguyen P.T., Thompson J.A., et al. Phase I clinical trial of allogeneic mixed lymphocyte culture (cytoimplant) delivered by endoscopic ultrasound-guided fine-needle injection in patients with advanced pancreatic carcinoma. Cancer 88 (2000) 1325-1355
114. Fazel A., and Draganov P. Interventional endoscopic ultrasound in pancreatic disease. Curr Gastroenterol Rep 6 (2004) 104-110
115. Kasuya H., Takeda S., Nomoto S., et al. The potential of oncolytic virus therapy for pancreatic cancer. Cancer Gene Ther 12 (2005) 725-736
116. Hecht J.R., Bedford R., Abbruzzese J.L., et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 9 (2003) 555-561